Welcome to our dedicated page for SBC Medical Group Holdings Incorporated SEC filings (Ticker: SBC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SBC Medical Group Holdings Incorporated (Nasdaq: SBC) SEC filings page on Stock Titan provides access to the company’s official disclosures filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed issuer with associated redeemable warrants trading under the symbol SBCWW, SBC submits a range of filings that document its financial condition, material events, and capital markets activity.
Among the most relevant documents for investors are current reports on Form 8-K, which SBC uses to announce material events such as quarterly financial results, tender offers and acquisitions, index inclusions, and capital strategy updates. For example, the company has filed 8-K reports to furnish press releases on quarterly results, to describe its inclusion in the Russell 3000 Index, and to summarize a tender offer for shares of Waqoo, Inc., a regenerative medicine research and development company. These filings provide detail on SBC’s operating performance, investment activities, and strategic direction.
Investors can also review filings related to capital structure and financing, including registration statements such as the company’s shelf registration on Form S-3. That registration statement, referenced in SBC’s news releases and 8-K filings, enables the company to offer and sell specified amounts of common and preferred stock in future offerings and also covers securities associated with its prior business combination transaction.
On Stock Titan, SBC’s filings are complemented by AI-powered summaries designed to help readers interpret complex regulatory documents. These summaries highlight key points from lengthy filings, such as the nature of material events disclosed in Form 8-K, the scope of registered securities in shelf filings, and the implications of tender offers or strategic investments. The page updates as new SBC filings are posted to the SEC’s EDGAR system, giving users a centralized view of the company’s regulatory history and ongoing disclosure record.
SBC Medical Group Holdings Incorporated reported consolidated assets of $315.3 million at June 30, 2025, up from $266.1 million a year earlier, driven by a cash balance of $152.7 million versus $125.0 million at December 31, 2024. For the six months ended June 30, 2025 the company recorded total revenues of $90.69 million, down from $107.91 million a year earlier, with related-party revenues comprising the majority at $84.20 million. Gross profit for the six-month period was $67.74 million and income from operations was $38.76 million, both lower year-over-year.
Net income attributable to SBC for the six months was $23.96 million ($0.23 per share), down from $37.24 million ($0.40 per share). Operating cash flow was an outflow of $6.41 million, offset by investing proceeds of $15.40 million largely from life insurance redemptions and financing inflows of $6.90 million, leaving ending cash higher. Key balance-sheet items include finance lease receivables of $22.33 million, long-term investments of $3.59 million, long-term investments in related MCs of $19.38 million, and 5 Bitcoins held at $535,882 fair value.
SBC Medical Group Holdings Incorporated furnished a press release and an investor presentation reporting results for the quarter ended June 30, 2025. The press release is included as Exhibit 99.1 and the investor presentation as Exhibit 99.2, with the presentation available on the company website at https://sbc-holdings.com/en/ir/ir-presentation. The report specifies these items are furnished, not filed under the Exchange Act and therefore are not subject to Section 18 liabilities. The company identifies as an emerging growth company and lists its common stock (SBC) and redeemable warrants (SBCWW) on The Nasdaq Stock Market LLC.